By rray, 31 December, 2014 If extraesophageal sx<sup>13</sup> persist despite PPI optimization: concomitant evaluation by ENT, pulmonary, and allergy specialists<sup>14</sup> [S/L]; if refractory after these evals negative: ambulatory reflux<sup>15</sup> monitoring [S/L]
By rray, 31 December, 2014 If typical/dyspeptic sx PPI-refractory: upper endoscopy<sup>13</sup> to r/o non-GERD etiologies [C/L]; if endoscopy negative: ambulatory reflux monitoring [S/L]; if tests negative, unlikely to have GERD, so discontinue PPI [S/L]
By rray, 31 December, 2014 If nocturnal sx, sleep disturbance, &/or variable schedules: consider dose-timing<sup>11</sup> adjustment &/or bid dosing [S/L]. Bedtime H2RA tx can be added prn to daytime PPI in pts w/ nighttime sx, but tachyphylaxis may occur after several wks [C/L].
By rray, 31 December, 2014 Increase PPI dosing<sup>11</sup> to bid or consider a switch to a different PPI<sup>12</sup> [C/L]
By rray, 31 December, 2014 After r/o cardiac cause: pts w/ noncardiac chest pain should have diagnostic eval before instituting tx [C/M]; consider dx eval w/ endoscopy<sup>8</sup> + pH monitoring, before a PPI trial.<sup>9</sup>